Clinical Trials
27 trialsNCT04285567 2026-03-03
CRISTALLO
Hoffmann-La Roche
Phase 3 Completed
NCT03609593 2026-02-25
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Columbia University
Phase 2 Completed
NCT03740529 2026-01-27
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
Phase 1/2 Completed
NCT05665530 2026-01-26
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Phase 1 Completed
NCT02296918 2025-12-19
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Phase 1 Completed
NCT02242942 2025-11-06
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT05105841 2025-10-15
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
AbbVie
Phase 2 Completed
NCT04512105 2025-09-11
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
University of California, Irvine
Phase 1 Completed
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT02910583 2024-12-20
Captivate
Pharmacyclics LLC.
Phase 2 Completed
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT03739554 2024-01-25
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
Cyclacel Pharmaceuticals, Inc.
Phase 1 Completed
NCT02005471 2023-10-17
MURANO
Hoffmann-La Roche
Phase 3 Completed
NCT03873857 2023-09-01
FORTE
AbbVie
Completed
NCT01682616 2023-06-06
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
AbbVie
Phase 1 Completed
NCT02756611 2023-04-10
VENICE I
AbbVie
Phase 3 Completed
NCT02980731 2023-02-22
VENICE II
AbbVie
Phase 3 Completed
NCT02758665 2023-01-17
CLL2-GiVe
University of Ulm
Phase 2 Completed
NCT02141282 2022-12-19
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
AbbVie
Phase 2 Completed
NCT01328626 2022-02-23
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
AbbVie
Phase 1 Completed
NCT02639910 2021-12-20
COSMOS
MorphoSys AG
Phase 2 Completed
NCT01889186 2021-12-16
A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion
AbbVie
Phase 2 Completed
NCT03045328 2021-09-29
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Stanford University
Phase 2 Completed
NCT02265731 2021-08-02
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
AbbVie
Phase 1/2 Completed
NCT03755947 2021-02-02
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia
Grupo Cooperativo de HemopatÃas Malignas
Phase 2 Completed
NCT01671904 2020-10-14
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 1 Completed
NCT01685892 2020-01-10
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
Genentech, Inc.
Phase 1 Completed